Lingrui Pharmaceutical shareholders approve key governance revisions

Henan Lingrui Pharmaceutical announced the resolutions from its first extraordinary general meeting of shareholders in 2025, held on November 18, 2025. A total of 313 shareholders and proxies, representing 170,801,018 shares or 30.1175% of the total voting shares, attended the meeting. All nine incumbent directors and three incumbent supervisors were present.

Shareholders passed all proposed resolutions, including a special resolution to abolish the supervisory board and amend the company's articles of association, which received 99.5979% of votes in favor. Other ordinary resolutions, such as revisions to the rules of procedure for shareholder meetings, board of directors meetings, and independent director work system, were also approved with substantial majorities, generally exceeding 98% of votes in favor.

Additional amendments to company policies, including those governing external guarantees, prevention of fund appropriation by controlling shareholders and related parties, related party transactions, and fundraising and authorization management, were all approved by shareholders. These approvals signify a comprehensive update to the company’s internal governance structures.